New dermatological agents for the treatment of psoriasis.
Thacher
S M
SM
Department of Biology, Allergan Inc., Irvine, California 92623, USA.
Vasudevan
J
J
Tsang
K Y
KY
Nagpal
S
S
Chandraratna
R A
RA
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000378:metabolism / Q000627:therapeutic use; D002762:Cholecalciferol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005938:Glucocorticoids; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008024:Ligands; D008727:Methotrexate / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects; D011987:Receptors, Steroid / Q000187:drug effects; D014801:Vitamin A / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D011987:Receptors, Steroid; D014801:Vitamin A; D002762:Cholecalciferol; D008727:Methotrexate